Welcome to the Novartis Sponsored Breakfast Symposium
The Evolving Adjuvant Treatment Landscape for HR+/HER2- Early Breast Cancer.
Novartis is pleased to welcome Breast Cancer Trials attendees to a dynamic and practical session exploring the evolving adjuvant treatment landscape for HR+/HER2- early breast cancer. The session is designed to enable discussion amongst the audience and the highly experienced panelists.
Renowned international expert Professor Stephen Chia will present the latest data from pivotal studies and discuss how emerging evidence is shaping treatment decisions.
Chaired by Dr Sanjeev Kumar, our expert panel of renowned specialists will then discuss how this evidence can be contextualised within Australia, exploring how oncologists are navigating shared decision-making, treatment management, the practicalities of delivering CDK4/6 inhibitors in real-world care, and quality of life considerations.
Agenda Highlights:
- The latest data from pivotal studies and how emerging evidence is shaping treatment decisions.
- How oncologists are navigating shared decision-making.
- Treatment management.
- The practicalities of delivering CDK4/6 inhibitors in real-world care.
- Quality of life considerations.
Don’t miss this opportunity to gain expert insights, explore real-world clinical considerations, and connect with peers in the oncology community. We look forward to seeing you there!
Meet our Guest Speakers
We are pleased to introduce the following speakers at the Novartis-sponsored Breakfast Symposium.
Stephen Chia
International Guest Speaker
Stephen Chia
International Guest Speaker
Dr Stephen Chia is a Full Professor in the Division of Medical Oncology, Head of the Division of Medical Oncology, UBC, and a staff medical oncologist with the BC Cancer, Vancouver Cancer Centre.
He has a full-time clinical practice focusing on breast cancer and new drug development. He is the Chair of the BC Cancer Breast Tumour Group and Head of the Department of Clinical Research. He is also the Co-Chair of the Breast Disease Site for the Canadian Cancer Trials Group (CCTG).
Dr Chia is recognized both nationally and internationally for his research work on breast cancer. His focus is on clinical trials and translational research.
He has published over 180 peer-reviewed papers. His publications appear in international peer-reviewed journals including high-impact journals such as the New England Journal of Medicine, Journal of Clinical Oncology, Lancet, Cell, JAMA Oncology, and Nature and Nature Medicine.
Dr Chia has been a Subject Editor for the British Journal of Cancer and The Oncologist and is the current section author for UpToDate™ in the Prognostic/ Predictive Markers Section. He holds numerous peer-reviewed grants.
Sanjeev Kumar
T&EC Day Guest Speaker
Sanjeev Kumar
T&EC Day Guest Speaker
Sanjeev is a Medical Oncologist and Clinician Scientist who grew up in country NSW, before completing undergraduate medical studies at the University of New South Wales in 2006. He trained as a Medical Oncologist at Royal Prince Alfred Hospital, the Chris O’Brien Lifehouse and in the United Kingdom.
Sanjeev moved to Cambridge (UK) in 2015 to undertake a fellowship in the Addenbrooke’s Hospital Cancer Drug Development Unit. He was then awarded a University of Cambridge scholarship in 2016 to complete a cancer molecular biology PhD at the Cancer Research UK Cambridge Institute, with a focus on Oestrogen receptor-positive breast cancer. Simultaneously, he ran a UK-wide clinical trial for patients with ER-positive breast cancer.
Sanjeev has returned to Australia to continue his clinical and academic focus on breast cancer with positions at Lifehouse, The Kinghorn Cancer Centre and the Garvan Institute of Medical Research. He has a keen interest in the education of trainees, public engagement and clinical trials.
Nicholas Wilcken
Symposium Guest Speaker
Nicholas Wilcken
Symposium Guest Speaker
Associate Professor Nicholas Wilcken was the Chair of the Breast Cancer Trials (BCT) Scientific Advisory Committee (SAC) from 2011 to March 2017. Associate Professor Wilcken is the Director of Medical Oncology at the Crown Princess Mary Cancer Centre, Westmead, and Associate Professor of Medicine at the University of Sydney.
His clinical interests are mainly in breast cancer, and his research interests include systematic reviews and breast cancer clinical trials. He is currently the Coordinating Editor of the Cochrane Collaboration’s Breast Cancer Group.
He has been an invited expert panel member for previous St Gallen Early Breast Cancer Consensus Conferences in Switzerland and is a member of the Steering Committee of the Early Breast Cancer Trialists’ Collaborative Group, based in Oxford, UK.
Maree Colosimo
Symposium Guest Speaker
Maree Colosimo
Symposium Guest Speaker
Dr Maree Colosimo is a medical oncologist who is committed to the survivorship of all her patients with cancer.
Dr Colosimo has a particular interest in the multidisciplinary treatment of breast cancer.
Dr Colosimo graduated from Monash University with a Bachelor of Medicine, Bachelor of Surgery with Honours in 1992 before moving to Queensland to undertake her specialist oncology training at the Royal Brisbane and Women’s Hospital in 1995.
Remaining in Brisbane after becoming a Fellow of the Royal Australasian College of Physicians, she has since worked as a medical oncologist across Brisbane and regional Queensland.
Dr Colosimo is also actively involved in translational research, looking at the best ways to translate clinical research into practice in order to enhance the health and well-being of all patients.
Hilary Martin
Symposium Guest Speaker
Hilary Martin
Symposium Guest Speaker
Dr Hilary Martin is a medical oncologist who subspecialises in the management of breast cancer.
After initial medical oncology training at Flinders Medical Centre and Calvary Hospital, Adelaide, she undertook a clinical fellowship with the Breast Cancer Unit at The Royal Marsden Hospital, London.
She currently works at Fiona Stanley Hospital as well as at the Perth Breast Cancer Institute.
Dr Martin has a keen interest in research. Her PhD focused on predictors of recurrence of hormone receptor-positive breast cancer, including mammographic breast density.
She has been the principal investigator of multiple investigator-initiated and pharmaceutical company-led clinical trials.
Her research spans a broad range of areas within breast cancer management, including fertility post-chemotherapy, exercise and cognition in breast cancer survivors, the management of endocrine therapy-related toxicities, and the use of estradiol PET scans for patients with a history of breast cancer.
Belinda Kiely
Conference Guest Speaker
Belinda Kiely
Conference Guest Speaker
Dr Belinda Kiely is a medical oncologist who specialises in breast cancer. She works at Campbelltown and Concord hospitals in Sydney, Australia.
She is an honorary clinical research fellow at the University of Sydney and enjoys supervising PhD students.
Her research interests include breast cancer treatment, survivorship, and prognostication in advanced cancer. Dr Kiely is an active member of Breast Cancer Trials.
She is the Australian study chair of the OPTIMA clinical trial and is the chair of the BCT Supportive Care Subgroup.
Dr Kiely is co-chair of the Medical Oncology Group of Australia Breast Cancer Group and a member of the Breast Cancer Network Australia Strategic Advisory Group.